Latham & Watkins Advises Boston Scientific in US$1.16 Billion Acquisition of Silk Road Medical

Boston Scientific Corporation (NYSE: BSX) has announced that it has entered into a definitive agreement to acquire Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR). The purchase price is US$27.50 per share, reflecting an enterprise value of approximately US$1.16 billion.

Latham & Watkins LLP represents Boston Scientific in the transaction with a corporate deal team led by Boston partner Julie Scallen and New York partner Ian Nussbaum, with M&A associates Shannon Cheng, Kennedy Holmes, Amy Lutfi, Rose Kenyon, Ivana Valdez, and Ashley Campfield, and intellectual property and licensing matters associate Oliver Mobasser. Advice was also provided on benefits and compensation matters by Boston partner Josh Friedman, with associates Rebecca Fishbein and Tessa Young; on tax matters by Washington, D.C. partner Nicholas J. DeNovio, with associates Abigail Friedman and Nolon Blaylock; on life sciences regulatory matters by Bay Area partner Betty Pang and Washington, D.C. partner Elizabeth Richards, with associates Leia Gu and Evan Miller; and on data privacy matters by Bay Area partner Heather Deixler, with associate Mitch Bennett.*

*Admitted to practice in New South Wales (Australia) only.